[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578679":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":80,"collaborators":10,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":10,"enrollmentInfo":91,"targetDuration":10,"studyType":94,"phases":10,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"GBA-PD Cohort",null,"Parkinson's disease (PD) patients diagnosed based on the \"United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria\". Patients in this group must have a documented heterozygous pathogenic variant in the GBA1 gene.",{"label":13,"type":10,"description":14,"interventionNames":10},"Idiopathic PD Cohort","This cohort includes patients diagnosed with Parkinson's disease (PD) based on the \"United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria\". Patients in this group do not have any documented heterozygous pathogenic variants in the GBA1 or LRRK2 genes.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Giulia Di Rauso, MD","CONTACT","+39 0522 296494","giulia.dirauso@ausl.re.it",[22,40,53,67],{"facility":23,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Ospedale A. Perrino","RECRUITING","Brindisi","Italy","IT",{"type":29,"coordinates":30},"Point",[31,32],17.93607,40.63215,{"lat":32,"lon":31},[35,38],{"name":36,"role":18,"phone":10,"phoneExt":10,"email":37},"Francesca Spagnolo, MD","francesca.spagnolo@asl.brindisi.it",{"name":36,"role":39,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":41,"status":24,"city":42,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"IRCCS Istituto Neurologico Carlo Besta","Milan",{"type":29,"coordinates":44},[45,46],12.59836,42.78235,{"lat":46,"lon":45},[49,52],{"name":50,"role":18,"phone":10,"phoneExt":10,"email":51},"Roberto Cilia, MD","roberto.cilia@istituto-besta.it",{"name":50,"role":39,"phone":10,"phoneExt":10,"email":10},{"facility":54,"status":24,"city":55,"state":10,"zip":56,"country":26,"countryCode":27,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Azienda USL IRCCS di Reggio Emilia","Reggio Emilia","42123",{"type":29,"coordinates":58},[59,60],10.63125,44.69825,{"lat":60,"lon":59},[63,66],{"name":64,"role":18,"phone":65,"phoneExt":10,"email":10},"Giulia Toschi, Clinical Research Coordinator","+390522295565",{"name":17,"role":39,"phone":10,"phoneExt":10,"email":10},{"facility":68,"status":24,"city":69,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Ospedale Santa Chiara di Trento","Trento",{"type":29,"coordinates":71},[72,73],11.12108,46.06787,{"lat":73,"lon":72},[76,79],{"name":77,"role":18,"phone":10,"phoneExt":10,"email":78},"Maria Chiara Malaguti, MD","mariachiara.malaguti@apss.tn.it",{"name":77,"role":39,"phone":10,"phoneExt":10,"email":10},{"type":81,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100578679","study-on-the-incidence-of-malignant-neoplasms-in-patients-with-parkinsons-disease-and-heterozygous-mutation-of-the-gba-gene-100578679",false,"NCT06814431","Study on the Incidence of Malignant Neoplasms in Patients With Parkinson's Disease and Heterozygous Mutation of the GBA Gene","ONCOGBA","Inclusion Criteria:\n\n* \\>18 years\n* Diagnosis of Parkinson's Disease through the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria for Parkinson's Disease.\n\nExclusion Criteria:\n\n* Uncertain diagnosis","ALL","18 Years",{"count":92,"type":93},3000,"ESTIMATED","OBSERVATIONAL","This multicenter retrospective observational study investigates the incidence of malignant neoplasms in Parkinson's disease (PD) patients carrying heterozygous pathogenic variants in the GBA1 gene. The study compares these patients to individuals with idiopathic PD and to the general population within a large national cohort.\n\nThe rationale for the study lies in the growing evidence indicating an increased risk of malignant neoplasms in patients affected by Gaucher disease.\n\nThe primary objective is to assess whether PD patients with GBA1 mutations have a higher incidence of malignant neoplasms compared to the general population. Secondary objectives include comparing the incidence of malignant neoplasms between GBA1-PD and idiopathic PD patients, as well as between idiopathic PD patients and the general population. Additionally, the study aims to characterize oncological conditions by sex, age, center, and tumor site, with specific attention to distinguishing hematologic tumors from solid tumors.\n\nBy identifying potential associations between GBA1 mutations and malignancies in PD, the findings could guide more comprehensive patient management, including screening for malignant neoplasms alongside Parkinson's disease care.",[97],"Idiopathic Parkinson's Disease (PD)",[99,100,101,102],"Parkinson's Disease","Neoplasms","GBA1","Genetic Parkinson's Disease","2026-07-23",{"date":105,"type":106},"2026-07-24","ACTUAL",{"date":108,"type":106},"2023-11-23",{"date":110,"type":93},"2026-12",{"name":5,"class":6},4]